Effects of traditional Korean medicine on anti-Müllerian hormone in patients with diminished ovarian reserve: A retrospective study  by Jo, Junyoung et al.
E
p
J
a
b
c
d
a
A
R
R
2
A
A
K
H
A
O
T
I
1
n
i
r
6
m
a
i
m
a
D
o
(
b
h
0
0Complementary Therapies in Medicine 24 (2016) 118–122
Contents lists available at ScienceDirect
Complementary Therapies  in  Medicine
jo ur nal home p ag e: www.elsev ierhea l th .com/ journa ls /c t im
ffects  of  traditional  Korean  medicine  on  anti-Müllerian  hormone  in
atients  with  diminished  ovarian  reserve:  A  retrospective  study
unyoung  Joa,b, Myung  Ja  Kangb, Jin  Moo  Leea,  Hyunho  Kimc, Ui  Min  Jerngd,∗
Department of Korean Gynecology, Graduate School, Kyung Hee University, Seoul 130-702, Republic of Korea
Department of Korean Gynecology, Conmaul Hospital, Seoul 137-881, Republic of Korea
Department of Biofunctional Medicine & Diagnostics, College of Korean Medicine, Kyung Hee University, Seoul 130-702, Republic of Korea
Clinical Research Division, Korea Institute of Oriental Medicine, Daejon 34054, Republic of Korea
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 20 November 2014
eceived in revised form
2 September 2015
ccepted 12 December 2015
vailable online 18 December 2015
eywords:
erbal medicine
nti-Müllerian hormone
a  b  s  t  r  a  c  t
Objective:  The  purpose  of  the  present  study  is  to retrospectively  evaluate  the effect  of  traditional  Korean
medicine  (TKM)  on  ovarian  reserve  by  measuring  serum  anti-Müllerian  hormone  (AMH)  levels  in  patients
with diminished  ovarian  reserve  (DOR).
Study  design:  We  performed  a retrospective  chart  review  of patients  with  DOR  who  had  received  TKM
for  at  least  2 months  and  had undergone  serum  AMH tests  before  and  after  TKM  treatment.  A total  of  22
patients  with  DOR were  included  in the  study.
Results:  There  were  no  signiﬁcant  differences  in  AMH  levels  before  and  after  TKM in all  patients  (n =  22,
p  =  0.237).  However,  when  the  study  population  was  divided  into  two  age  groups  (<38  (n = 12) and  ≥38
years  (n  =  10))  to  determine  whether  there  was  a age-related  difference  in  the  effect  of  TKM  with  DOR,  avarian reserve
raditional Korean medicine
nfertility
signiﬁcant  increase  in AMH  levels  before  and  after  TKM  was  observed  in  the  age  <38  (p <  0.05).
Conclusions:  TKM  may  provide  an  effective  option  for patients  aged  <38  years  with  DOR, but  it  should
be  interpreted  cautiously  as more  rigorous  research  is needed.  Further  studies  in a larger  population
are  needed  to  conﬁrm  these  results  and  to evaluate  the  effects  of  improved  ovarian  reserve  on  fertility
outcomes  following  TKM  in  patients  with  DOR.
©  2016  The  Authors.  Published  by Elsevier  Ltd.  This  is an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Infertility is deﬁned by the failure to achieve a successful preg-
ancy after 12 months or more of appropriate, timed unprotected
ntercourse or therapeutic donor insemination.1 The infertility rate
anged from 3.5% to 16.7% in more developed nations and from
.9% to 9.3% in less-developed nations, with an estimated overall
edian prevalence of 9%.2 In Korea, the infertility rate was  reportedpproximately 13.5% by Korea Institute for Health and Social Affairs
n 2003.3
Abbreviations: AMH, anti-Müllerian hormone; TKM, traditional Korean
edicine; DOR, diminished ovarian reserve; FSH, follicle stimulating hormone; ART,
ssisted reproductive technology; IVF, in vitro fertilization; HM, herbal medicine;
HEA, dehydroepiandrosterone; SD, standard deviation.
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965-2299/© 2016 The Authors. Published by Elsevier Ltd. This is an open access article 
/).license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Ovarian reserve, deﬁned as a woman’s remaining follicular pool,
declines with advancing age.4 Diminished ovarian reserve (DOR) is
deﬁned when the size and quantity of the remaining ovarian follicu-
lar pool is smaller than expected at any given age.5 DOR, also known
as age-related infertility, is an important and challenging aspect of
assisted reproductive technology (ART) because infertile women
with DOR are at risk for reduced natural fecundability and have
lower pregnancy rates and higher rates of cycle cancellation.6,7
Despite the availability of various treatment options for patients
with DOR, no consensus exists regarding the most effective treat-
ment approach.6
The most widely used laboratory test in the assessment of ovar-
ian reserve is measurement of follicle stimulating hormone (FSH).8
However, over the last few years, anti-Müllerian hormone (AMH)
has emerged as a key marker of ovarian reserve.9 A big potential
advantage of AMH  over FSH measurement as a clinical test is that
AMH  levels are stable throughout the menstrual cycle and hence
serum can be drawn randomly.8
AMH  is secreted by the granulosa cells of growing follicles. AMH
appears to better reﬂect the total quantity of the remaining follicu-
lar pool, and, therefore, is a better marker of declining reproductive
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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bility.9 AMH  has been reported as a predictor of natural fecund-
bility and has been positively associated with pregnancy and live
irth rates after assisted reproduction.7,10
Acupuncture and herbal medicine (HM) has been widely used
n reproductive medicine.11,12 A study reported that 22% of the
ouples had utilized acupuncture and 17% used HM as a modal-
ty for treatment of infertility.13 Acupuncture has been used to
anage ovulation disorders, and it has been shown to improve
regnancy outcomes in women undergoing in vitro fertilization
IVF).11,14 Pharmacopuncture, also known as acupoint injection, is
 new therapy that combines acupuncture therapy with the injec-
ion of pharmacological medication or puriﬁed herbal medicine to
cupoints.15 Pharmacopuncture provokes higher de-qi sensation
ompared to traditional acupuncture, which might be an indica-
ion that pharmacopuncture provides a stronger clinical response
han traditional acupuncture.16 Two systematic reviews have also
uggested that HM can improve pregnancy rates among female
nfertility patients undergoing IVF.17,18
Traditional Korean medicine (TKM), including pharmacopunc-
ure and HM,  has been widely used in patients with infertility in
orea. It is reported that about 60% of infertile patients had tried
KM treatment before using assisted reproduction by Korea Insti-
ute for Health and Social Affairs in 2012.19 However, there have
een no studies about the effects of TKM on AMH  in patients with
OR. The aims of the present study were to investigate the effect of
KM on ovarian reserve by measuring AMH  levels in patients with
OR.
. Materials and methods
.1. Subjects
We  performed a retrospective chart review of patients with
OR who presented at the Department of Gynecology of Korean
edicine, Conmaul Hospital, Seoul, Republic of Korea, from March
013 to June 2015. The institutional review board of Kyung Hee
niversity Korean Medicine Hospital at Gangdong approved this
etrospective observational study; the requirement of patient
pproval or informed consent for the review of medical records
as waived (KHNMCOH 2014-10-002).
The eligibility criteria for inclusion were female outpatients who
ad been treated for DOR for at least 2 months and had under-
one AMH  tests before and after TKM treatment. TKM treatment
as started within two weeks after the serum AMH  level test and
econd AMH  test was conducted within two weeks after TKM treat-
ent during follicular phase of menstrual cycle. There were no
estrictions in terms of age, body mass index. We  re-evaluated the
MH level to assess the effect of the TKM treatment for at least
 month treatment in our clinic based on the criterion which in
stablished dehydroepiandrosterone (DHEA) studies.4,6 DOR was
eﬁned as AMH level <1.1 ng/mL.20,21 Exclusion criteria were: (1)
atients with primary ovarian insufﬁciency; (2) contraceptive pill
se for at least four weeks prior to the study; (3) hormone replace-
ent therapy; (4) cancer treatments or gonadotropin treatment.
.2. Serum anti-Müllerian hormone analysis
Serum AMH  levels were measured before and after TKM treat-
ents at the laboratories of GC Labs, Yongin (AMH: AMH  Gen IInzyme-linked immunosorbent assay [ELISA], Beckman Coulter,
SA). The detection limit of the assay was 0.08 ng/mL. The intra- and
nter-assay coefﬁcients of variation were 12.3% and 14.2%, respec-
ively.in Medicine 24 (2016) 118–122 119
2.3. Therapeutic intervention
The therapeutic interventions for patients with DOR were
the same as those described in our previous study in 2010.22
These treatments included (1) water-extracted decoctions
(120 mL)  of herbal prescriptions customized to individual
pattern diagnosis and given two  times a day 30 min after
meals. These herbal prescriptions were Soyoondam-tang,
Anjunyichun-tang, Bohyuldodam-tang, Yukmihabyiseon-tang,
and Gamiyorkbohabyiseon-tang. Detailed compositions of herbal
prescriptions are shown in Table 1. (2) One pack of Seung Keum
Dan taken with warm water three times a day 30 min  before
meals. This HM formula contains 214 mg of dried powder of
Moutan Radicis Cortex,  Ligustici Tenuissimi Rhizoma et Radix, Gin-
seng Radix, Angelicae Gigantis Radix, Poria Sclerotium,  Angelicae
Dahuricae Radix, Cinnamomi Cortex,  Cnidii Rhizoma, Corydalis Tuber,
Paeoniae Radix, and Atractylodis Rhizoma Alba and 107 mg of dried
powder of Glycyrrhizae Radix et Rhizoma and Achyranthis Radix
per pack; (3) moxibustion to CV8 at home once daily, except
during the menstrual period; and (4) pharmacopuncture injection
of extracted solution of dried Cervi parvum cornu and Hominis
placenta, which were prepared in the laboratories of the Korean
Pharmacopuncture Institute (KPI), 0.1 mL  of each, mainly at CV4,
BL19, and BL22, using a sterile insulin syringe (29 gauge and 1/2
inch, Shinchang, Gyeongsangbuk-do, Republic of Korea).22 The
HM and pharmacopuncture treatments were administered by two
doctors of Korean medicine (K.M.D.) with ten years of clinical and
research experience.
2.4. Statistical analysis
SPSS 19.0 for Windows (SPSS Inc., Chicago, IL, USA) was  used
for data management and statistical analysis. All continuous vari-
ables are expressed as means ± standard deviation (SD). Wilcoxon
signed-rank test was  used to measure the difference between val-
ues at baseline and at the end of treatment. We  divided the study
population into two age groups (<38 years and ≥38 years) to deter-
mine whether there was an age-related difference in the effect of
TKM in patients with DOR as a post hoc analysis. Age 38 was  chosen
as cut-off because it has been reported to represents the beginning
of accelerated decline in ovarian reserve.4 All p-values <0.05 were
considered statistically signiﬁcant.
3. Results
A total of 245 patients took AMH  test, and of these 34 patients
with AMH  level <1.1 ng/mL took AMH  test again after TKM treat-
ment. We  screened 34 patients’ medical records, and 12 patients
of them were excluded because they were with primary ovarian
insufﬁciency. Finally, 22 patients with DOR were included in the
study. Baseline descriptive parameters for all patients are shown
in Table 1. The baseline AMH  levels of four patients were unde-
tectable. We postulated undetectable values as 0.08 because the
detection limit of the AMH  assay was  0.08 ng/mL. There were no sig-
niﬁcant differences in AMH  levels before and after TKM treatment
in all patients (p = 0.237) (Table 2). However, when the study popu-
lation was  divided into two age groups (<38 years and ≥38 years) to
determine whether there was an age-related difference in the effect
of TKM in patients with DOR, there were signiﬁcant differences in
AMH  levels before and after TKM treatment in the younger group
(p < 0.05) (Table 3). The AMH  levels in the younger group increased
from 0.30 ± 0.26 ng/mL before treatment to 0.63 ± 0.59 ng/mL after
treatment. No adverse effects were observed during the treatments.
After TKM treatment, two  patients conceived spontaneously were
ongoing at 34 and 36 gestational weeks and one patient gave birth
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Table  1
Compositions of herbal medicines.
Korean medicine formulae Compositions & dose (per day)
Soyoondam-tang Cyperi Rhizoma 9 g, Citri Unshius Pericarpium 4.5 g, Bupleuri Radix 4 g, Liriopis seu Ophiopogonis Tuber 4 g,
Atractylodis Rhizoma Alba 4 g, Angelicae Gigantis Radix 4 g, Paeoniae Radix 4 g, Zingiberis Rhizoma Recens 4 g, Zizyphi
Fructus 4 g, Pinelliae Tuber 3 g, Ponciri Fructus Immaturus 3 g, Phyllostachyos Caulis in Taeniam 3 g, Ginseng Radix
2.25 g, Platycodonis Radix 2.25 g, Menthae Herba 2 g, Glycyrrhizae Radix et Rhizoma 2 g
Anjunyichun-tang Ginseng Radix 20 g, Rehmanniae Radix Preparata 20 g, Atractylodis Rhizoma Alba 20 g, Dioscoreae Rhizoma 10 g, Corni
Fructus 10 g, Eucommiae Cortex 6 g, Dolichoris Semen 4 g, Lycii Fructus 4 g, Glycyrrhizae Radix et Rhizoma 2 g
Bohyuldodam-tang Rehmanniae Radix Preparata 12 g, Cyperi Rhizoma 9 g, Angelicae Gigantis Radix 8 g, Atractylodis Rhizoma Alba 6 g,
Cnidii Rhizoma 6 g, Paeoniae Radix 6 g, Citri Unshius Pericarpium 4.5 g, Poria Sclerotium 4 g, Amomi  Fructus Rotundus
4  g, Amomi  Fructus 4 g, Eucommiae Cortex 4 g, Dipsaci Radix 4 g, Zingiberis Rhizoma Recens 4 g, Pinelliae Tuber 3 g,
Ponciri Fructus Immaturus 3 g, Phyllostachyos Caulis in Taeniam 3 g, Zizyphi Fructus 3 g, Liriopis seu Ophiopogonis
Tuber 2.25 g, Bupleuri Radix 2.25 g, Ginseng Radix 2.25 g, Platycodonis Radix 2.25 g, Crataegi Fructus 2 g, Massa
Medicata Fermentata 2 g, Hordei Fructus Germinatus 2 g, Glycyrrhizae Radix et Rhizoma 2 g
Yukmihabyiseon-tang Rehmanniae Radix Preparata 16 g, Dioscoreae Rhizoma 8 g, Corni Fructus 8 g, Poria Sclerotium 6 g, Moutan Radicis
Cortex 6 g, Alismatis Rhizoma 6 g, Epimedii Herba 12 g, Curculiginis Rhizoma 12 g, Angelicae Gigantis Radix 9 g,
Morindae Radix 9 g, Anemarrhenae Rhizoma 5 g, Phellodendri Cortex 5 g
Gamiyorkbohabyiseon-tang Japanese Angelicae Radix 6 g, Liriopis seu Ophiopogonis Tuber 5.2 g, Paeoniae Radix 5.2 g, Bupleuri Radix 5.2 g,
Asparagi Tuber 5.2 g, Dioscoreae Rhizoma 5.2 g, Alismatis Rhizoma 5.2 g, Atractylodis Rhizoma Alba 4.8 g, Poria
Sclerotium 4.8 g, Citri Unshius Pericarpium 4.8 g, Fritillariae Thunbergii Bulbus 4.8 g, Cyperi Rhizoma 4.8 g, Lycii
Radicis Cortex 4.8 g, Moutan Radicis Cortex 4 g, Menthae Herba 4 g, Glycyrrhizae Radix et Rhizoma 4 g, Epimedii Herba
12  g, Curculiginis Rhizoma 12 g, Angelicae Gigantis Radix 9 g, Morindae Radix 9 g, Anemarrhenae Rhizoma 5 g,
Phellodendri Cortex 5 g
Table 2
Clinical parameters, including anti-Müllerian hormone (AMH) levels, in all patients before and after traditional Korean medicine (TKM) therapies.
Before TKM therapies (n = 22) After TKM therapies (n = 22) p-Value
Age (years) 36.68 ± 6.18 – –
Body  mass index (kg/m2) 20.42 ± 2.09 – –
Duration of treatment (months) 3.64 ± 1.43
AMH  (ng/mL) 0.30 ± 0.29 0.42 ± 0.49 0.237
Values are given as means ± standard deviation.
AMH—anti-Müllerian hormone.
Table 3
Anti-Müllerian hormone (AMH) levels in patients aged <38 or ≥38 years before and after traditional Korean medicine (TKM) therapies.
Age <38 years, n = 12 p-Value Age ≥38 years, n = 10 p-Value
Before TKM therapies After TKM therapies Before TKM therapies After TKM therapies
Duration of treatment (months) 4.17 ± 1.59 – 3.00 ± 0.94 –
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alues are given as means ± standard deviation.
MH—anti-Müllerian hormone.
o twins through ART treatment. The results for all patients are
hown in Table 4.
. Discussion
We  found that TKM therapies were associated with signiﬁcant
ncrements in serum AMH  concentrations in DOR patients who
ere <38 years old. To our knowledge, this study is the ﬁrst to
resent objective evidence that AMH  levels can be improved with
KM in patients with DOR. However, TKM therapies did not affect
igniﬁcantly serum AMH  levels in patients aged 38 years and older
elated with physiological ovarian ageing.
To evaluate the effect of TKM therapies in DOR patients, prospec-
ive randomized clinical trials are needed. But TKM therapies
ombining acupuncture and HM are usually utilized to achieve bet-
er effect in real clinic for DOR patients. There were few studies
valuating this clinical setting. To explore the role of TKM in the
reatment of DOR, retrospective chart review would be better than
andomized clinical trials.0.021 0.29 ± 0.35 0.18 ± 0.14 0.263
4.1. Mechanisms of action
According to TKM physiological theory, reproductive and
endocrine systems are related to the ‘kidney’. Women  with nor-
mal  fecundability have been considered to have abundant ‘kidney
qi’ as well as essence and blood in TKM.23 The HM and pharma-
copuncture therapies in the present study are used on the purpose
of regulating ‘kidney yin yang’, replenishing essence and blood, and
stimulating the proper ﬂow of ’qi’.
It has been suggested that HM can promote the luteotropic
release of estrogen and progesterone in the ovary and stimulate
the synthesis and pulsatile secretion of gonadotropins in the pitu-
itary in anovulatory infertile women.24 The mechanism of action
has not been fully elucidated, but it is believed that HM might
reduce resistance in ovarian blood ﬂow and increase ovarian per-
fusion, thus promoting follicular development. Consequently, HM
improves oocyte quality and embryo quality and can result in
higher pregnancy rates.14
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Table  4
Patient characteristics and anti-Müllerian hormone (AMH) levels during the study.
Patient Number Age Duration of treatment
(months)
Number of acupuncture
treatments
Dosage of herbal
medicine (days)
AMH level (ng/mL)
Water extracted decoction Seung Keum Dan Before treatment After treatment
1 42 6 15 150 135 0.7 0.53
2  44 5 11 100 80 UD 0.12
3  43 6 21 100 132 0.30 0.16
4  44 2 11 60 60 0.16 0.08
5  40 3 11 75 40 0.08 0.08
6  36 2 3 65 32 0.67 0.98
7  35 4 11 110 80 UD 0.37
8  35 6 31 180 95 0.11 0.08
9  32 4 11 100 30 UD 1.99
10  36 3 7 70 35 UD 0.08
11  19 3 6 60 15 0.36 0.77
12  44 6 29 180 120 0.08 0.08
13  32 3 13 60 30 0.62 1.01
14  42 3 11 60 15 0.14 0.08
15  30 2 10 60 15 0.08 0.08
16  27 2 7 60 20 0.27 0.23
17  39 4 9 60 130 1.12 0.48
18  37 3 10 60 40 0.62 1.1
19  38 3 13 60 75 0.3 0.08
20  34 5 22 135 60 0.08 0.08
21  41 2 9 60 50 0.08 0.25
22  37 3 6 60 15 0.61 0.74
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.2. Comparison with relevant literature
One of the most controversial issues in reproductive medicine is
he question of whether DOR can be treated pharmacologically.25
o date, no treatment regimen for patients with DOR has been
hown to be effective.6 It has been proposed that oral administra-
ion of DHEA may  improve ovarian response and pregnancy rates in
omen with DOR during IVF, but there are insufﬁcient data to sup-
ort a beneﬁcial role of DHEA as an adjuvant to controlled ovarian
timulation during the IVF cycle.26
Several studies have shown that AMH  levels were improved
fter DHEA supplementation.4,6 One study reported that the AMH
evel was increased by 0.43 ng/mL after DHEA supplementation
or at least 6 weeks, and the results and the age of that study
roup are comparable to our study.6 Another study showed signiﬁ-
ant improvement in AMH  levels following DHEA supplementation
specially in women aged <38 years.4 The ﬁnding that the ther-
peutic effects were more pronounced in a younger group with
remature ovarian aging was in line with our result, and the degree
f improvement of AMH  levels was comparable to ours.4 Both stud-
es reported that it appears to increase the chance of pregnancy
mong DOR patients, both spontaneously and while undergoing
RT with improvement of AMH  levels.4,6 In this context, our result
hat AMH  level was increased by 0.33 ng/mL after TKM treatment
ight be meaningful to increase the fecundability. Future trials
omparing the effects of TKM and DHEA are needed.
.3. Limitations
This study has the inherent limitations of retrospective research.
lso, the sample sizes were very small. Although serum AMH  levels
ere signiﬁcantly increased in women under the age of 38 years, we
ould not follow up all the patients on pregnancy outcomes. Further
tudies in a larger population and longer prospective randomized
linical trials are needed in order to conﬁrm these results and to
valuate the effects of improved ovarian reserve following TKM on
regnancy outcomes in patients with DOR.5. Conclusions
TKM may  provide an effective option for patients aged <38 years
with DOR, but it should be interpreted cautiously because this study
was exploratory study for feasibility of TKM in patients with DOR.
Further rigorous studies in a larger population are needed in order
to conﬁrm these results and to evaluate the effects of improved
ovarian reserve after TKM on pregnancy outcomes in patients with
DOR.
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